Full Press Release Details
Disclaimer This presentation has been prepared by I-Mab (the
"Company") solely for information purpose. By viewing or accessing the information contained in this material, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied, are made by the
Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness, or correctness of the information or opinions presented or
contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising
from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not
guaranteed. This presentation does not constitute an offer to sell or issue or an invitation or recommendation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No securities of the Company
may be sold in the United States without registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act of 1933, as amended (the "Securities
Act") and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or investment decision in relation to any securities or otherwise. This presentation does
not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this presentation
shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you
will be independent of this presentation and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own
view of the potential future performance of the business of the Company. Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act
and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company's intent, beliefs, or current expectations about the future. These statements can be recognized by the use of words such as
"expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident," or words of similar meaning. These
forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual
results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers, or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or
circumstances. THE INFORMATION CONTAINED HEREIN IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED,
REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. Any forwarding, distribution, or reproduction of this presentation in whole or in part is unauthorized. By viewing, accessing, or participating in this
presentation, you hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. You agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such
documents are provided. You agree further not to photograph, copy, or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. You
must return this presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing, or participating in this presentation, you agree to be bound by the foregoing
limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. 2 I-MAB INVESTOR PRESENTATIONDisclaimer This presentation has been prepared by I-Mab (the "Company") solely for
information purpose. By viewing or accessing the information contained in this material, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied, are made by the Company or any of its directors,
shareholders, employees, agents, affiliates, advisors, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness, or correctness of the information or opinions presented or contained in this presentation.
None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or
contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed. This presentation does not
constitute an offer to sell or issue or an invitation or recommendation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No securities of the Company may be sold in the United States without
registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act of 1933, as amended (the "Securities Act") and the rules and regulations
thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information
relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this presentation shall be relied upon as a promise or
representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this
presentation and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future
performance of the business of the Company. Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements reflect the Company's intent, beliefs, or current expectations about the future. These statements can be recognized by the use of words such as "expects,"
"plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident," or words of similar meaning. These forward-looking
statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ
materially from these forward-looking statements. The Company or any of its affiliates, advisers, or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances. THE
INFORMATION CONTAINED HEREIN IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR
OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. Any forwarding, distribution, or reproduction of this presentation in whole or in part is unauthorized. By viewing, accessing, or participating in this presentation, you
hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. You agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such documents are
provided. You agree further not to photograph, copy, or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. You must return this
presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing, or participating in this presentation, you agree to be bound by the foregoing limitations. Any failure to
comply with these restrictions may constitute a violation of applicable securities laws. 2 I-MAB INVESTOR PRESENTATION
Key Investment Highlights Novel or Highly Clinical Stage Commercial
Stage $500m+ Raised Differentiated Company in 2 Years Nasdaq listed Immuno-oncology Expected product From private 8 late-stage and and autoimmune launch 2021 rounds 2016-2019 early-stage assets disease onwards and IPO 2020 Moving towards a fully
integrated Founded as a discovery global biopharma in 3-5 years focused start-up in 2016 3 I-MAB INVESTOR PRESENTATIONKey Investment Highlights Novel or Highly Clinical Stage Commercial Stage $500m+ Raised Differentiated Company in 2 Years Nasdaq
listed Immuno-oncology Expected product From private 8 late-stage and and autoimmune launch 2021 rounds 2016-2019 early-stage assets disease onwards and IPO 2020 Moving towards a fully integrated Founded as a discovery global biopharma in 3-5 years
focused start-up in 2016 3 I-MAB INVESTOR PRESENTATION
I-Mab Transitioning from I-Mab 1.0 to I-Mab 2.0 A Commercial stage
company with full scale R&D and manufacture capability Serial BLA filings expected from 2021 onwards Fully Integrated Global A clinical stage company with Biopharma global operations 2024 8-10 clinical programs in US and China I-Mab 2.0
Delivering clinical and corporate catalysts 2020 Building commercial capability/partnership Building manufacture capability Nasdaq Listing Expanding global and regional partnerships I-Mab 1.0 Global portfolio of 12
assets 2016 China portfolio of 5 licensed clinical assets Raised US$ 500m from private rounds and IPO R&D capability and global footprint Focusing on Novel and Highly Differentiated Biologics COMPANY OVERVIEW 4 I-MAB
INVESTOR PRESENTATIONI-Mab Transitioning from I-Mab 1.0 to I-Mab 2.0 A Commercial stage company with full scale R&D and manufacture capability Serial BLA filings expected from 2021 onwards Fully Integrated Global A clinical stage company with
Biopharma global operations 2024 8-10 clinical programs in US and China I-Mab 2.0 Delivering clinical and corporate catalysts 2020 Building commercial capability/partnership Building manufacture capability Nasdaq Listing
Expanding global and regional partnerships I-Mab 1.0 Global portfolio of 12 assets 2016 China portfolio of 5 licensed clinical assets Raised US$ 500m from private rounds and IPO R&D capability and global
footprint Focusing on Novel and Highly Differentiated Biologics COMPANY OVERVIEW 4 I-MAB INVESTOR PRESENTATION
Innovative and Risk-Balanced Pipeline: Two Portfolios China China
Strategy - Fast-to-Market 5 clinical assets BLA 2021 onwards Global In - li cen si ng China Discovery Pre-Clinical IND Enabling Phase 1 / Phase 2 Phase 3 BLA Marketing China US Global Partnership Global Global Strategy - Fast-to-PoC
Internal R&D Clinical Validation 12 clinical & pre-clinical assets Rockville, MD Shanghai Beijing COMPANY OVERVIEW 5 I-MAB INVESTOR PRESENTATIONInnovative and Risk-Balanced Pipeline: Two Portfolios China China Strategy - Fast-to-Market
5 clinical assets BLA 2021 onwards Global In - li cen si ng China Discovery Pre-Clinical IND Enabling Phase 1 / Phase 2 Phase 3 BLA Marketing China US Global Partnership Global Global Strategy - Fast-to-PoC Internal R&D Clinical Validation
12 clinical & pre-clinical assets Rockville, MD Shanghai Beijing COMPANY OVERVIEW 5 I-MAB INVESTOR PRESENTATION
Innovative Pipeline of Novel and Highly Differentiated Potential
Expected Indication/ Commercial Drug Candidate (Licensor) Preclinical Phase 1 Phase 2 Phase 3 NDA / BLA Therapeutic Area Rights Filing (1) TJ202 (MorphoSys) Multiple myeloma/ Greater China BLA 2021 Autoimmune disease Differentiated CD38 antibody (2)
Pediatric growth Eftansomatropin TJ101 (Genexine) Greater China BLA 2023 hormone deficiency Long-acting growth hormone Olamkicept TJ301 (Ferring) Ulcerative colitis/ Greater China 2021-2024 Soluble gp130 IL-6 inhibitor Autoimmune disease S. Korea
(3) Head and neck Enoblituzumab (MacroGenics) Greater China cancer/ Oncology B7-H3 antibody Efineptakin TJ107 (Genexine) Oncology-related Greater China Novel long-acting IL-7 lymphopenia Autoimmune TJM2 disease/Cytokine Global GM-CSF antibody
release syndrome TJC4 Multiple cancer Global Differentiated CD47 antibody indications Multiple cancer TJD5 Global indications Differentiated CD73 antibody TJ210 (MorphoSys) Oncology/ Greater China 2024- Differentiated C5aR antibody Autoimmune
disease Global shared TJX7 Autoimmune disease Global Novel CXCL13 antibody (4) Bi-specific antibody panel Multiple cancer Global including five PD-L1-based bi- indications Some shared specifics, TJ-C4GM and TJ- CLDN4B Notes 1. TJ202 has two ongoing
registrational trials, a monotherapy trial and a combination therapy trial in relapsed or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus erythematosus ("SLE") in the first half
of 2020 2. For TJ101, we expect to submit an IND for a Phase 3 registrational trial in China by early 2020 3. For enoblituzumab, we expect to initiate either a registrational trial or a Phase 2 trial (pending NMPA's regulatory approval) by the
end of 2020 4. Our bi-specific antibody panel consists of (i) five PD-L1-based bi-specific antibodies, including TJ-L1I7 (PD-L1 and IL-7 cytokine fusion), TJ-L1C4 (PD-L1 and CD47), TJ-L1D5 (PD-L1 and CD73), TJ-L1H3 (PD-L1 and B7-H3), and TJ-L14B
(PD-L1 and 4-1BB), (ii) TJ-C4GM (anti-CD47 and GM- CSF), and (iii) TJ CLDN4B (Claudin 18.2 and 4-1BB) COMPANY OVERVIEW 6 I-MAB INVESTOR PRESENTATION Global Portfolio China PortfolioInnovative Pipeline of Novel and Highly Differentiated Potential
Expected Indication/ Commercial Drug Candidate (Licensor) Preclinical Phase 1 Phase 2 Phase 3 NDA / BLA Therapeutic Area Rights Filing (1) TJ202 (MorphoSys) Multiple myeloma/ Greater China BLA 2021 Autoimmune disease Differentiated CD38 antibody (2)
Pediatric growth Eftansomatropin TJ101 (Genexine) Greater China BLA 2023 hormone deficiency Long-acting growth hormone Olamkicept TJ301 (Ferring) Ulcerative colitis/ Greater China 2021-2024 Soluble gp130 IL-6 inhibitor Autoimmune disease S. Korea
(3) Head and neck Enoblituzumab (MacroGenics) Greater China cancer/ Oncology B7-H3 antibody Efineptakin TJ107 (Genexine) Oncology-related Greater China Novel long-acting IL-7 lymphopenia Autoimmune TJM2 disease/Cytokine Global GM-CSF antibody
release syndrome TJC4 Multiple cancer Global Differentiated CD47 antibody indications Multiple cancer TJD5 Global indications Differentiated CD73 antibody TJ210 (MorphoSys) Oncology/ Greater China 2024- Differentiated C5aR antibody Autoimmune
disease Global shared TJX7 Autoimmune disease Global Novel CXCL13 antibody (4) Bi-specific antibody panel Multiple cancer Global including five PD-L1-based bi- indications Some shared specifics, TJ-C4GM and TJ- CLDN4B Notes 1. TJ202 has two ongoing
registrational trials, a monotherapy trial and a combination therapy trial in relapsed or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus erythematosus ("SLE") in the first half
of 2020 2. For TJ101, we expect to submit an IND for a Phase 3 registrational trial in China by early 2020 3. For enoblituzumab, we expect to initiate either a registrational trial or a Phase 2 trial (pending NMPA's regulatory approval) by the
end of 2020 4. Our bi-specific antibody panel consists of (i) five PD-L1-based bi-specific antibodies, including TJ-L1I7 (PD-L1 and IL-7 cytokine fusion), TJ-L1C4 (PD-L1 and CD47), TJ-L1D5 (PD-L1 and CD73), TJ-L1H3 (PD-L1 and B7-H3), and TJ-L14B
(PD-L1 and 4-1BB), (ii) TJ-C4GM (anti-CD47 and GM- CSF), and (iii) TJ CLDN4B (Claudin 18.2 and 4-1BB) COMPANY OVERVIEW 6 I-MAB INVESTOR PRESENTATION Global Portfolio China Portfolio
The Emerging Value Drivers: Critical Product Differentiation Clinical
Assets Key Differentiation Clinical Development Plan Short infusion time (0.5 - 2 hrs) and lower IRR (7%) Two on-going registrational trials in MM to target TJ202 BLA in 2021 Differentiated CD38 mAb Ph 1b trial in SLE in 2020
nd Combination with Lenalidomide as 2 line therapy Convenient weekly dosing vs. daily injections TJ101 Planned IND for Ph 3 in PGHD in mid 2020 Differentiated BLA expected in 2023 long-acting hGH Better safety profile (HyFc) vs.
pegylated hGH Strong anti-tumor activity US trial on-going in solid tumor/lymphoma: Minimal binding to RBC due to a unique epitope Safety advantage (dose-escalation, 1-30 mg/kg) TJC4 Combination with PD-1/CD20 Differentiated CD47 mAb
No severe anemia (GLP tox up to 100 mg/kg) China trial starting: AML/MDS Intra-dimerization mechanism: no "hook effect" US trial on-going: Phase 1 combo with PD-L1 TJD5 China trial starting: Phase 1 combo with PD-1
Differentiated CD73 mAb MoA with broader tumor indications COMPANY OVERVIEW 7 I-MAB INVESTOR PRESENTATIONThe Emerging Value Drivers: Critical Product Differentiation Clinical Assets Key Differentiation Clinical Development Plan Short infusion time
(0.5 - 2 hrs) and lower IRR (7%) Two on-going registrational trials in MM to target TJ202 BLA in 2021 Differentiated CD38 mAb Ph 1b trial in SLE in 2020 nd Combination with Lenalidomide as 2 line therapy Convenient weekly
dosing vs. daily injections TJ101 Planned IND for Ph 3 in PGHD in mid 2020 Differentiated BLA expected in 2023 long-acting hGH Better safety profile (HyFc) vs. pegylated hGH Strong anti-tumor activity US trial on-going in solid
tumor/lymphoma: Minimal binding to RBC due to a unique epitope Safety advantage (dose-escalation, 1-30 mg/kg) TJC4 Combination with PD-1/CD20 Differentiated CD47 mAb No severe anemia (GLP tox up to 100 mg/kg) China trial starting:
AML/MDS Intra-dimerization mechanism: no "hook effect" US trial on-going: Phase 1 combo with PD-L1 TJD5 China trial starting: Phase 1 combo with PD-1 Differentiated CD73 mAb MoA with broader tumor indications COMPANY
OVERVIEW 7 I-MAB INVESTOR PRESENTATION
TJC4: Minimal Binding to Red Blood Cells by Design RBC Agglutination 1 2
T J C 4 5 F 9 2 A 1 9 IgG 6 5F9 3 2A1 0 TJC4 g / m l RBC Binding 1 0 0 8 0 IgG 6 0 TJC4 4 0 5F9 2 0 0 2A1 I g G T J C 4 5 F 9 2 A 1 COMPANY OVERVIEW 8 I-MAB INVESTOR PRESENTATION 0 . 0 0 3 0 . 0 1 0 . 0 3 0 . 1 0 . 3 1 3 1 0 3 0 1 0 0 % o f R
B C b i n d i n g A g g l u t i n a t i o n i n d e xTJC4: Minimal Binding to Red Blood Cells by Design RBC Agglutination 1 2 T J C 4 5 F 9 2 A 1 9 IgG 6 5F9 3 2A1 0 TJC4 g / m l RBC Binding 1 0 0 8 0 IgG 6 0 TJC4 4 0 5F9 2 0 0 2A1 I g G T J
C 4 5 F 9 2 A 1 COMPANY OVERVIEW 8 I-MAB INVESTOR PRESENTATION 0 . 0 0 3 0 . 0 1 0 . 0 3 0 . 1 0 . 3 1 3 1 0 3 0 1 0 0 % o f R B C b i n d i n g A g g l u t i n a t i o n i n d e x
TJC4: Safety Advantage Demonstrated in Cyno Monkeys Pilot-single dose
4-wk GLP-Tox R B C s H e m o g l o b i n P B S 6 P B S 1 6 R B C s 5 F 9 5 F 9 1 4 5 T J C 4 T J C 4 7 1 2 V e h i c l e 4 1 0 6 T J C 4 ( 1 0 m g / k g ) 3 8 T J C 4 ( 3 0 m g / k g ) 5 6 2 T J C 4 ( 1 0 0 m g / k g ) 4 4 1 Male 2 3 0 0 - 8 - 4 0 4
8 1 2 1 6 2 0 2 4 - 8 - 4 0 4 8 1 2 1 6 2 0 2 4 2 D a y D a y 1 0 - 1 4 - 7 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 D a y s Pilot-repeat dose R B C s 7 V e h i c l e T J C 4 ( 1 0 m g / k g ) 6 T J C 4 ( 3 0 m g / k g ) 5 R B C s H e m o g l o b i n T J C 4
( 1 0 0 m g / k g ) 4 7 P B S 1 6 P B S Female T J C 4 T J C 4 1 4 6 3 1 2 5 2 1 0 4 8 1 3 6 0 2 4 - 1 4 - 7 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 1 2 D a y s 0 0 0 7 1 4 2 1 2 8 3 5 0 7 1 4 2 1 2 8 3 5 D a y s D a y s COMPANY OVERVIEW 9 I-MAB INVESTOR
PRESENTATION 1 2 1 2 R B C c o u n t s ( 1 0 / L ) R B C c o u n t s ( 1 0 / L ) H e m o g l o b i n ( g / d L ) H e m o g l o b i n ( g / d L ) 1 2 1 2 R B C c o u n t s ( 1 0 / L ) R B C c o u n t s ( 1 0 / L )TJC4: Safety Advantage Demonstrated